ViCentra has raised $13m in the second close of its Series D funding round that will be directed towards advancing commercialisation efforts for its Kaleido insulin patch pump.
The Dutch medtech company’s latest Series D close brings its total funds for the round to $98m, following an initial $85m close on the round in September 2025. With the latest tranche, ViCentra’s overall funding stands at around $200m, as per data from GlobalData’s Medical Intelligence Centre.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Funds from the second close originated from Dutch business development agency ROM Ultrecht Region and Dutch investors including Venturing Tech. Existing investor Innovation Industries also participated.
ViCentra’s Kaleido wearable insulin patch pump is designed for people with type 1 diabetes. CE-marked in October 2024 under the European Union’s Medical Device Regulation (EU MDR), the pump uses pulse technology to provide continuous micro-dosing of insulin.
As with the first tranche from ViCentra’s Series D close, the company said it will apply the additional funds towards scaling its manufacturing provision and deepening its commercial execution in Germany, the Netherlands, and France. According to ViCentra, since its $85m fund raise in September, it has since doubled its European user base to over 4,000 and has been focused on expanding its manufacturing capacity to meet this “surging demand”.
ViCentra restated that it also plans to use the cumulative Series D funds towards accelerating preparations for the pump’s regulatory submission with the US Food and Drug Administration (FDA).
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataViCentra’s CEO Tom Arnold said: “This latest funding enables us to further scale our manufacturing capabilities, strengthen our commercial presence and support in Germany, the Netherlands, and France, and ensures that we remain on course for our planned US market access.
“Our goal for 2026 is clear: convert our current high demand into satisfied users through uncompromising quality and performance and nearly triple our European user base by the end of 2026.”
In the US, the insulin pump market remains competitive. According to a GlobalData market model, while Dexcom led the combined insulin pump and continuous glucose monitoring (CGM) market with a 20.2% share in 2024, Abbott led the market in 2025 with a 22.5% share, followed by Dexcom and Insulet with market share of 16.2% and 14.5%, respectively.
